Karmanos Cancer Institute
Karmanos Cancer Institute, headquartered in Detroit and a subsidiary of McLaren Health Care, is the largest cancer research and provider network in Michigan with 16 treatment locations throughout Michigan and Ohio. This expanding network provides cancer patients with increased access to advanced cancer care in communities throughout the state.
Caring for approximately 12,000 new patients annually and conducting more than 800 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation’s best cancer centers. Karmanos offers one of the largest clinical trials program in the nation, giving patients access to more than 250 promising new treatments often not found at other hospitals or health organizations.
Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, Karmanos strives to lead in transformative cancer care, research and education through courage, commitment and compassion. Our long-term partnership with the Wayne State University School of Medicine enhances the collaboration of critical research and academics related to cancer care.
Why Choose Karmanos?
We work with hundreds of doctors to arrange for convenient care for patients and families. Together, our cancer teams and your doctor can recommend the best treatment options with immediate access to the latest cancer-fighting drugs and therapies. At Karmanos we’ll make sure your first chance at beating cancer is your best chance toward a future free of cancer.
Karmanos Cancer Center is the only National Cancer Institute (NCI) - designated comprehensive cancer center in metro Detroit and one of just 54 centers of its kind in the United States. That means patients can access treatments exclusive to Karmanos as well as clinical trials, cancer prevention programs and multidisciplinary teams of cancer specialists - a comprehensive approach you cannot find at a community hospital. Because comprehensive cancer centers are at the forefront of cancer research, they can often handle patient cases that are more complex.
To receive the NCI designation, a hospital must demonstrate expertise in research, laboratory, clinical and population-based research. Hospitals must also provide early-phase clinical trials and conduct community outreach and educational activities. Karmanos is conducting more than 800 cancer-specific scientific investigation programs and clinical trials.
The scientific advances Karmanos researchers make every day help determine treatment options and guide treatment courses. We’re at the forefront of offering treatments that define the new standards of care. Our research programs, which are unique to Karmanos, are bringing safe, effective and groundbreaking treatments from the laboratory bench to the patient’s bedside. In fact, Karmanos offers more cancer treatments not found elsewhere in Michigan.
For more information, visit www.karmanos.org